醫療新知DAPA-HF試驗揭示:Dapagliflozin顯著改善心力衰竭患者的生存質量 Posted on 2024-01-032024-01-26 by Wine-Font 03 1 月 Continue reading →
醫療新知心衰患者新希望:Dapagliflozin對不同NT-proBNP水平患者的顯著治療效果 Posted on 2024-01-032024-01-26 by Wine-Font 03 1 月 Continue reading →
醫療新知突破性心衰治療:Dapagliflozin對不同射血分數患者的全面效益 Posted on 2024-01-022024-01-26 by Wine-Font 02 1 月 Continue reading →
醫療新知突破性研究:達格列净有效改善輕度降低或保持正常的心臟射血分數患者心臟衰竭情況 Posted on 2024-01-022024-01-26 by Wine-Font 02 1 月 Continue reading →
醫療新知ADVANCE試驗揭示:關鍵生物標誌物預測2型糖尿病患者心臟衰竭風險 Posted on 2023-12-292024-01-26 by Wine-Font 29 12 月 Continue reading →
醫療新知糖尿病患者心衰風險評估新突破:TnT和NT-proBNP的聯合預測價值 Posted on 2023-12-292024-01-26 by Wine-Font 29 12 月 Continue reading →
醫療新知突破性發現:BNP和NT-proBNP在心臟功能評估中的雙重角色揭示 Posted on 2023-12-282024-01-26 by Wine-Font 28 12 月 Continue reading →
醫療新知突破性發現:NT‐proBNP能有效預測高風險2型糖尿病患者的死亡和心血管事件 Posted on 2023-08-082024-01-26 by Wine-Font 08 8 月 Continue reading →
醫療新知創新CANDLE試驗揭示:Canagliflozin對2型糖尿病患者與心臟衰竭間的新希望 Posted on 2023-08-082024-01-26 by Wine-Font 08 8 月 Continue reading →
醫療新知突破性研究發現:新生物標誌物對2型糖尿病心血管風險有重大預測價值 Posted on 2023-08-082024-01-26 by Wine-Font 08 8 月 Continue reading →
醫療新知新研究揭示:NT-proBNP水準與糖尿病風險和併發症的關聯 Posted on 2023-07-272024-02-21 by Wine-Font 27 7 月 Continue reading →